C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026)

C4 Therapeutics has reported Accumulated Expenses for 8 years, with the latest figure at $9.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 22.19% year-over-year to $9.8 million; the trailing twelve-month figure through Mar 2026 stood at $9.8 million (down 22.19% YoY), and the FY2025 full-year result was $13.3 million, down 31.24% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $9.8 million, down from $13.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $20.6 million in Q4 2023, with the low at $6.7 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $14.7 million, with a median of $15.4 million recorded in 2024.
• Year-over-year, Accumulated Expenses surged 529.94% in 2022 and tumbled 33.03% in 2024.
• Tracing CCCC's Accumulated Expenses over 5 years: stood at $19.8 million in 2022, then rose by 4.36% to $20.6 million in 2023, then fell by 6.14% to $19.4 million in 2024, then slumped by 31.24% to $13.3 million in 2025, then declined by 26.17% to $9.8 million in 2026.
• The last three Accumulated Expenses figures came in at $9.8 million (Q1 2026), $13.3 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.

Peer Comparison